行情

PLX

PLX

PROTALIX生物疗法
AMEX

实时行情|Nasdaq Last Sale

0.2078
-0.0098
-4.50%
已收盘, 16:00 11/12 EST
开盘
0.2105
昨收
0.2176
最高
0.2149
最低
0.2050
成交量
32.95万
成交额
--
52周最高
0.6000
52周最低
0.1700
市值
3,083.38万
市盈率(TTM)
-1.1963
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PLX 新闻

  • 沪指低开震荡 纳指再创新高、期金连跌四日
  • 新浪财经.2小时前
  • 美国最大牛奶公司Dean Foods申请破产保护
  • 澎湃新闻.3小时前
  • 外媒:瑞银在香港收天价罚单
  • 参考消息.3小时前
  • 多数分析师仍预期日央行继续宽松 但相反看法者大增
  • 新浪财经综合.3小时前

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

PLX 简况

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
展开

Webull提供Protalix Biotherapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。